Understanding how ME2 loss affects pancreatic cancer growth
Molecular Basis of ME2-mediated Tumor Suppression in Pancreatic Cancer
This study is looking at how a gene called ME2 affects the growth and spread of pancreatic cancer, with the hope of finding new treatments that could help patients live longer and better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-10994014 on NIH RePORTER |
What this research studies
This research investigates the role of the ME2 gene in pancreatic cancer, particularly how its loss contributes to tumor growth and spread. By using advanced cell culture techniques and mouse models, the team aims to uncover the molecular mechanisms behind ME2's impact on cancer progression. The goal is to identify new personalized treatment options that could improve survival rates for patients with pancreatic ductal adenocarcinoma. This work is crucial as it addresses the urgent need for novel therapies in a disease known for its poor prognosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with genetic alterations involving the ME2 gene.
Not a fit: Patients with pancreatic cancer who do not have ME2 loss or other relevant genetic alterations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new personalized therapies that significantly improve survival for pancreatic cancer patients.
How similar studies have performed: Previous research has shown promise in targeting genetic alterations in pancreatic cancer, suggesting that this approach could yield significant advancements.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Singh, Pankaj Kumar — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Singh, Pankaj Kumar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.